R&D Changing Faces: Board of Directors and Advisory Boards, Marc... Board‑level appointments this month were thick and fast, with six Boards adding new faces as Chairperson.
R&D Changing Faces: Board of Directors and Advisory Boards, Febr... Boardrooms and advisory panels across pharma, biotech, medtech, and digital health were busy last month.
R&D Changing Faces: Board of Directors, January 2026 January was a relatively quiet month for Board news, but there were some notable moves here and there.
R&D Changing Faces: Board appointments, November and December 20... As 2025 came to a close, we also saw a modest number of Board appointments, on both advisory and governance Boards.
R&D Changing Faces – Board of Directors and Advisory Boards - Oc... From high-profile resignations to the addition of seasoned executives and scientific leaders, last month saw a series of notable changes.
R&D Changing Faces – Boards of Directors and Advisory Boards – A... Welcome back to Changing Faces, in our final round-up for August and September there are plenty of Board appointments to report on.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
